Clinical Trials Logo

Meibomian Gland Dysfunction clinical trials

View clinical trials related to Meibomian Gland Dysfunction.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06324890 Recruiting - Dry Eye Clinical Trials

PET-CT Imaging Features of Meibomian Glands

Start date: January 31, 2024
Phase:
Study type: Observational

Analysis the results of Dry eye analysis results and PET-CT imaging comprehensively

NCT ID: NCT06287879 Recruiting - Dry Eye Clinical Trials

Function and Morphological Characteristics of Meibomian Gland in Patients With Renal Anemia

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Renal anemia refers to anemia in which the absolute or relative production of erythropoietin (EPO) is insufficient due to various kidney diseases, and uremic toxins affect erythropoietin production and its lifespan. Common treatment drugs for renal anemia include erythropoietin EPO and Roxadustat (FG-4592). Medical history information was collected from patients with renal anemia who visited the ophthalmology department with dry eye symptoms. This study will help to determine the function and morphological characteristics of meibomian gland in patients with renal anemia

NCT ID: NCT06220474 Recruiting - Dry Eye Syndromes Clinical Trials

Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The goal of this prospective, 24-week, double-masked, randomized, sham-controlled clinical trials to compare clinical efficacy and safety of RF and MGX with MGX alone in patients with meibomian gland dysfunction-related dry eye disease. The main question it aims to answer is whether radiofrequency treatment and meibomian gland expression is more effective in improving tear breakup time, as measured using non-invasive video keratography, compared with meibomian gland expression alone, in patients with refractory meibomian gland dysfunction-related dry eye disease. Participants will be divided into two groups, one group will receive RF treatment followed with MGX and another will receive sham treatment with MGX.

NCT ID: NCT06154200 Recruiting - Clinical trials for Aqueous Tear Deficiency

Eyelid Androgen Treatment in Dry Eye

Start date: April 2, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to evaluate the effectiveness and safety of applying androgen sex hormone (i.e., testosterone) gel on the eyelids in the treatment of dry eye patients. Several studies have demonstrated positive treatment effects in dry eye, but few have applied testosterone gels to the eyelids.

NCT ID: NCT06064071 Recruiting - Dry Eye Disease Clinical Trials

Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD

Start date: September 18, 2023
Phase: N/A
Study type: Interventional

Clinical Study Evaluating Nordlys™ System with Selective Waveband Technology (SWT)® Intense Pulsed Light (IPL) Applicators for Dry Eye Disease (DED) due to Meibomian Gland Dysfunction (MGD).

NCT ID: NCT06004895 Recruiting - Dry Eye Syndromes Clinical Trials

Mechanisms of Light-based Therapies for Dry Eye Disease

MOLT
Start date: October 25, 2023
Phase: N/A
Study type: Interventional

Dry eye disease is a common condition affecting millions worldwide and costing millions in healthcare due to reduced work productivity and quality of life. The disruption of oil glands in our eyelids known as Meibomian glands, which produce the oily layer of our tears to protect it from evaporating, is one of the most common contributors of dry eye disease. Much effort has been put into developing effective treatments for this condition as new treatments are constantly being introduced to the market. The purpose of this clinical trial is to investigate how proven light-based therapies work in treating dry eye disease and oil gland disruption. These therapies include intense-pulsed light therapy (IPL) which uses a series of light flashes on the facial skin surface, and low-level light therapy (LLLT) which uses a mask with a series of light-emitting diodes (LEDs) to warm the body cells. The main questions it aims to answer are: 1. What are the short- and long-term changes associated with these treatments on the eyelids and surface of the eyes? 2. Does LLLT alone work better than IPL+LLLT in treating dry eye disease and oil gland disruption? Participants with dry eye disease and oil gland disruption will receive four treatments with these light-based therapies each separated by two to three weeks apart, and followed up two to three weeks and three months after the final treatment session. One eye of the participant will receive intense pulsed light together with low-level light therapy, while the other eye will receive only low-level light therapy with a sham intense pulsed light treatment so that the researchers can compare if clinical signs and symptoms improve in one eye more than the other.

NCT ID: NCT05598437 Recruiting - Dry Eye Syndromes Clinical Trials

Prevalence of Different Etiologies of Ocular Dryness in Patients Previously Diagnosed With Dry Eye Disease in A Sample of Egyptian Patients

Start date: November 1, 2022
Phase:
Study type: Observational

Proposed Study Title: Prevalence of Different Etiologies of Ocular Dryness in Patients Previously Diagnosed with Dry Eye

NCT ID: NCT05383612 Recruiting - Dry Eye Clinical Trials

To Evaluate the Efficacy of Diquafosol Sodium in the Treatment of MGD in Different Treatment Pattern

Start date: August 5, 2022
Phase: N/A
Study type: Interventional

MGD is a chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal duct obstruction and/or qualitative/quantitative changes in the glandular secretion. It may result in alteration of the tear film, symptoms of eye irritation, clinically apparent inflammation, and ocular surface disease. The meibomian glands, found in the upper and lower eyelids, excrete lipids onto the ocular surface that forms the outermost layer of the tear film, lubricating the ocular surface during blinking and protecting against tear evaporation.1 2 Through dysfunction of the meibomian glands, reduced lipid secretion may contribute to tear film instability and entry into the vicious circle of dry eye disease. The prevalence of MGD is higher in Asian populations, ranging from 46% to 70%. The management and treatment subcommittee of the International Workshop on MGD proposed a treatment algorithm in which treatment is added depending on the severity of MGD. The sequence of treatment addition is eyelid hygiene, eyelid warming and massage, artificial lubricants, topical azithromycin, topical emollient lubricant, oral tetracycline derivatives, lubricant ointment, and anti-inflammatory therapy. Topical diquafosol solution has been used to treat dry eye because it increases fluid secretion from conjunctival epithelial cells and mucin secretion from conjunctival goblet cells via the P2Y2 receptor. Because P2Y2 receptor expression is observed in sebaceous cells and ductal cells in the meibomian gland, diquafosol is expected to have some effects on meibomian glands. it has been reported that use 3% diquafosol ophthalmic solution in patients with obstructive MGD for more than 4 months. Ocular symptoms, lid margin abnormalities, the superficial punctate keratopathy score, and the meibum grade were decreased, while the tear breakup time, tear film meniscus area, and meibomian gland area were increased. These results suggest that topical diquafosol therapy is effective for patients with obstructive MGD. However, so far, no studies have reported the effect of DQS combined with eyelid hot compress and eyelid gland massage for MGD.

NCT ID: NCT05306561 Recruiting - Dry Eye Clinical Trials

Evaluating Impact of Systane iLux on Dryness Symptoms and Wearing Time in Contact Lens Users

Start date: January 26, 2022
Phase: N/A
Study type: Interventional

To evaluate dry eye symptoms and contact lens wearing times after a single iLux treatment by evaluating change from baseline in OSDI scores, subjective CLDEQ8 and CL wearing time questionnaires, and meibomian gland secretion scores.

NCT ID: NCT05165342 Recruiting - Clinical trials for Meibomian Gland Dysfunction

Effectiveness and Safety of High Frequency Electrotherapy in Patients With Meibomian Gland Dysfunction

Start date: December 2021
Phase: N/A
Study type: Interventional

This study is a prospective randomized double-masked sham-controlled clinical trial to determine the clinical improvement, safety and mechanism of action by evaluation inflammatory cytokine, and amount of bacteria and demodex, after high frequency electrotherapy or called quantum molecular resonance treatment in patients with meibomian gland dysfunction.